The nociceptin/orphanin FQ receptor (NOP) as a target for drug abuse medications

Current Topics in Medicinal Chemistry

Volumn 11, Issue 9, 2011, Pages 1151-1156

  Zaveri, Nurulain T ^a  

^a Astraea Therapeutics Inc   (Spain)

Author keywords

Drug addiction; Mixed action opioids; Nociceptin receptor ligands; NOP ligands; NOP receptor; NOP opioid ligands; Polydrug addiction

Indexed keywords

8 (2,3,3A,4,5,6 HEXAHYDRO 1H PHENALEN 1 YL) 1 PHENYL 1,3,8 TRIAZASPIRO[4.5]DECAN 4 ONE; ALCOHOL; AMPHETAMINE; ANXIOLYTIC AGENT; BENZODIAZEPINE; BUPRENORPHINE; CHLORDIAZEPOXIDE; COCAINE; DELTA OPIATE RECEPTOR; DIAMORPHINE; DOPAMINE; KAPPA OPIATE RECEPTOR; MORPHINE; MU OPIATE RECEPTOR; NALOXONE; NALTREXONE; NOCICEPTIN RECEPTOR; NOCICEPTIN RECEPTOR AGONIST; SCH 221510; SR 16435; UNCLASSIFIED DRUG;

ALCOHOL CONSUMPTION; ALCOHOLISM; ANOREXIA; ARTICLE; DOPAMINE RELEASE; DRUG ABUSE; DRUG TOLERABILITY; FLUID INTAKE; HUMAN; MORPHINE ADDICTION; MOTIVATION; NOCICEPTION; NONHUMAN; PAIN; RESPIRATION DEPRESSION; STRESS; WITHDRAWAL SYNDROME;

ALCOHOLISM; ANALGESICS, OPIOID; ANIMALS; BEHAVIOR, ADDICTIVE; BUPRENORPHINE; COCAINE; DOPAMINE; DRUG COMBINATIONS; HUMANS; IMIDAZOLES; LIGANDS; MICE; MICE, KNOCKOUT; MORPHINE; OPIOID PEPTIDES; PSYCHOTROPIC DRUGS; RATS; RECEPTORS, OPIOID; SPIRO COMPOUNDS; SUBSTANCE-RELATED DISORDERS;

EID: 79954546900     PISSN: 15680266     EISSN: None     Source Type: Journal    
DOI: 10.2174/156802611795371341     Document Type: Article

References (82)

1. Kenna, G. A.; Nielsen, D. M.; Mello, P.; Schiesl, A.; Swift, R. M. Pharmacotherapy of dual substance abuse and dependence. CNS Drugs, 2007, 21, 213-237.
2. Mollereau, C.; Parmentier, M.; Mailleux, P.; Butour, J. L.; Moisand, C.; Chalon, P.; Caput, D.; Vassart, G.; Meunier, J. C. ORL1, a novel member of the opioid receptor family. Cloning, functional expression and localization. FEBS Lett., 1994, 341, 338.
3. Wang, J. B.; Johnson, P. S.; Imai, Y.; Persico, A. M.; Ozenberger, B. A.; Eppler, C. M.; Uhl, G. R. cDNA cloning of an orphan opiate receptor gene family member and its splice variant. FEBS Lett., 1994, 348, 75-79.
4. Bunzow, J. R.; Saez, C.; Mortrud, M.; Bouvier, C.; Williams, J. T.; Low, M.; Grandy, D. K. Molecular cloning and tissue distribution of a putative member of the rat opioid receptor gene family that is not a mu, delta or kappa opioid receptor type. FEBS Lett., 1994, 347, 284-288.
5. Meunier, J. C.; Mollereau, C.; Toll, L.; Suaudeau, C.; Moisand, C.; Alvinerie, P.; Butour, J. L.; Guillemot, J. C.; Ferrara, P.; Monsarrat, B. Isolation and structure of the endogenous agonist of opioid receptor-like ORL1 receptor. Nature, 1995, 377, 532-535.
6. Reinscheid, R. K.; Nothacker, H. P.; Bourson, A.; Ardati, A.; Henningsen, R. A.; Bunzow, J. R.; Grandy, D. K.; Langen, H.; Monsma, F. J., Jr.; Civelli, O. Orphanin FQ: a neuropeptide that activates an opioidlike G protein-coupled receptor. Science, 1995, 270, 792-794.
7. Gintzler, A. R.; Adapa, I. D.; Toll, L.; Medina, V. M.; Wang, L. Modulation of enkephalin release by nociceptin (orphanin FQ). Eur. J. Pharmacol., 1997, 325, 29-34.
8. Mogil, J. S.; Pasternak, G. W. The molecular and behavioral pharmacology of the orphanin FQ/nociceptin peptide and receptor family. Pharmacol. Rev., 2001, 53, 381-415.
9. Mogil, J. S.; Grisel, J. E.; Reinscheid, R. K.; Civelli, O.; Belknap, J. K.; Grandy, D. K. Orphanin FQ is a functional anti-opioid peptide. Neurosciences, 1996, 75, 333-337.
10. Mogil, J. S.; Grisel, J. E.; Zhangs, G.; Belknap, J. K.; Grandy, D. K. Functional antagonism of mu-, delta-and kappa-opioid antinociception by orphanin FQ. Neurosci. Lett., 1996, 214, 131-134.
11. Zeilhofer, H. U.; Calo, G. Nociceptin/orphanin FQ and its receptor-potential targets for pain therapy?. J. Pharmacol. Exp. Ther., 2003, 306, 423-429.
12. Fioravanti, B.; Vanderah, T. W. The ORL-1 receptor system: are there opportunities for antagonists in pain therapy? Curr. Top. Med. Chem., 2008, 8, 1442-1451.
13. Lambert, D. G. The nociceptin/orphanin FQ receptor: a target with broad therapeutic potential. Nat. Rev. Drug Discov., 2008, 7, 694-710.
14. Jenck, F.; Moreau, J. L.; Martin, J. R.; Kilpatrick, G. J.; Reinscheid, R. K.; Monsma, F. J., Jr.; Nothacker, H. P.; Civelli, O. Orphanin FQ acts as an anxiolytic to attenuate behavioral responses to stress. Proc. Natl. Acad. Sci. USA, 1997, 94, 14854-14858.
15. Griebel, G.; Perrault, G.; Sanger, D. J. Orphanin FQ, a novel neuropeptide with anti-stress-like activity. Brain Res., 1999, 836, 221-224.
16. Jenck, F.; Wichmann, J.; Dautzenberg, F. M.; Moreau, J. L.; Ouagazzal, A. M.; Martin, J. R.; Lundstrom, K.; Cesura, A. M.; Poli, S. M.; Roever, S.; Kolczewski, S.; Adam, G.; Kilpatrick, G. A synthetic agonist at the orphanin FQ/nociceptin receptor ORL1: anxiolytic profile in the rat. Proc. Natl. Acad. Sci. USA, 2000, 97, 4938-4943.
17. Varty, G. B.; Hyde, L. A.; Hodgson, R. A.; Lu, S. X.; McCool, M. F.; Kazdoba, T. M.; Del Vecchio, R. A.; Guthrie, D. H.; Pond, A. J.; Grzelak, M. E.; Xu, X.; Korfmacher, W. A.; Tulshian, D.; Parker, E. M.; Higgins, G. A. Characterization of the nociceptin receptor (ORL-1) agonist, Ro64-6198, in tests of anxiety across multiple species. Psychopharmacology, (Berl), 2005, 182, 132-143.
18. Varty, G. B.; Lu, S. X.; Morgan, C. A.; Cohen-Williams, M. E.; Hodgson, R. A.; Smith-Torhan, A.; Zhang, H.; Fawzi, A. B.; Graziano, M. P.; Ho, G. D.; Matasi, J.; Tulshian, D.; Coffin, V. L.; Carey, G. J. The anxiolytic-like effects of the novel, orally active nociceptin opioid receptor agonist 8-[bis(2-methylphenyl)methyl]-3-phenyl-8-azabicyclo[3.2.1]octan-3-ol (SCH 221510). J. Pharmacol. Exp. Ther., 2008, 326, 672-682.
19. Ciccocioppo, R.; Cippitelli, A.; Economidou, D.; Fedeli, A.; Massi, M. Nociceptin/orphanin FQ acts as a functional antagonist of corticotropin-releasing factor to inhibit its anorectic effect. Physiol. Behav., 2004, 82, 63-68.
20. Ciccocioppo, R.; Martin-Fardon, R.; Weiss, F.; Massi, M. Nociceptin/ orphanin FQ inhibits stress-and CRF-induced anorexia in rats. Neuroreport, 2001, 12, 1145-1149.
21. Martin-Fardon, R.; Ciccocioppo, R.; Massi, M.; Weiss, F. Nociceptin prevents stress-induced ethanol-but not cocaine-seeking behavior in rats. Neuroreport, 2000, 11, 1939-1943.
22. Neal, C. R., Jr.; Mansour, A.; Reinscheid, R.; Nothacker, H. P.; Civelli, O.; Akil, H.; Watson, S. J., Jr. Opioid receptor-like (ORL1) receptor distribution in the rat central nervous system: comparison of ORL1 receptor mRNA expression with (125)I-[(14)Tyr]-orphanin FQ binding. J. Comp. Neurol., 1999, 412, 563-605.
23. Neal, C. R., Jr.; Mansour, A.; Reinscheid, R.; Nothacker, H. P.; Civelli, O.; Watson, S. J., Jr. Localization of orphanin FQ (nociceptin) peptide and messenger RNA in the central nervous system of the rat. J. Comp. Neurol., 1999, 406, 503-547.
24. Di Giannuario, A.; Pieretti, S. Nociceptin differentially affects morphine-induced dopamine release from the nucleus accumbens and nucleus caudate in rats. Peptides, 2000, 21, 1125-1130.
25. Di Giannuario, A.; Pieretti, S.; Catalani, A.; Loizzo, A. Orphanin FQ reduces morphine-induced dopamine release in the nucleus accumbens: a microdialysis study in rats. Neurosci. Lett., 1999, 272, 183-186.
26. Murphy, N. P.; Maidment, N. T. Orphanin FQ/nociceptin modulation of mesolimbic dopamine transmission determined by microdialysis. J. Neurochem., 1999, 73, 179-186.
27. Murphy, N. P.; Ly, H. T.; Maidment, N. T. Intracerebroventricular orphanin FQ/nociceptin suppresses dopamine release in the nucleus accumbens of anaesthetized rats. Neuroscience., 1996, 75, 1-4.
28. Murphy, N. P.; Lee, Y.; Maidment, N. T. Orphanin FQ/nociceptin blocks acquisition of morphine place preference. Brain Res., 1999, 832, 168-170.
29. Ciccocioppo, R.; Angeletti, S.; Sanna, P. P.; Weiss, F.; Massi, M. Effect of nociceptin/orphanin FQ on the rewarding properties of morphine. Eur. J. Pharmacol., 2000, 404, 153-159.
30. Kotlinska, J.; Wichmann, J.; Legowska, A.; Rolka, K.; Silberring, J. Orphanin FQ/nociceptin but not Ro 65-6570 inhibits the expression of cocaine-induced conditioned place preference. Behav. Pharmacol., 2002, 13, 229-235.
31. Sakoori, K.; Murphy, N. P. Central administration of nociceptin/ orphanin FQ blocks the acquisition of conditioned place preference to morphine and cocaine, but not conditioned place aversion to naloxone in mice. Psychopharmacology (Berl), 2004, 172, 129-136.
32. Zhao, R. J.; Woo, R. S.; Jeong, M. S.; Shin, B. S.; Kim, D. G.; Kim, K. W. Orphanin FQ/nociceptin blocks methamphetamine place preference in rats. Neuroreport, 2003, 14, 2383-2385.
33. Kotlinska, J.; Rafalski, P.; Biala, G.; Dylag, T.; Rolka, K.; Silberring, J. Nociceptin inhibits acquisition of amphetamine-induced place preference and sensitization to stereotypy in rats. Eur. J. Pharmacol., 2003, 474, 233-239.
34. Ciccocioppo, R.; Panocka, I.; Polidori, C.; Regoli, D.; Massi, M. Effect of nociceptin on alcohol intake in alcohol-preferring rats. Psychopharmacol. (Berl), 1999, 141, 220-224.
35. Kuzmin, A.; Sandin, J.; Terenius, L.; Ogren, S. O. Acquisition, expression, and reinstatement of ethanol-induced conditioned place preference in mice: effects of opioid receptor-like 1 receptor agonists and naloxone. J. Pharmacol. Exp. Ther., 2003, 304, 310-318.
36. Ciccocioppo, R.; Economidou, D.; Cippitelli, A.; Cucculelli, M.; Ubaldi, M.; Soverchia, L.; Lourdusamy, A.; Massi, M. Genetically selected Marchigian Sardinian alcohol-preferring (msP) rats: an animal model to study the neurobiology of alcoholism. Addict. Biol., 2006, 11, 339-355.
37. Economidou, D.; Hansson, A. C.; Weiss, F.; Terasmaa, A.; Sommer, W. H.; Cippitelli, A.; Fedeli, A.; Martin-Fardon, R.; Massi, M.; Ciccocioppo, R.; Heilig, M. Dysregulation of nociceptin/ orphanin FQ activity in the amygdala is linked to excessive alcohol drinking in the rat. Biol. Psychiatry, 2008, 64, 211-218.
38. Ciccocioppo, R.; Economidou, D.; Fedeli, A.; Angeletti, S.; Weiss, F.; Heilig, M.; Massi, M. Attenuation of ethanol self-administration and of conditioned reinstatement of alcohol-seeking behaviour by the antiopioid peptide nociceptin/orphanin FQ in alcohol-preferring rats. Psychopharmacology (Berl), 2004, 172, 170-178.
39. Carra, G.; Rizzi, A.; Guerrini, R.; Barnes, T. A.; McDonald, J.; Hebbes, C. P.; Mela, F.; Kenigs, V. A.; Marzola, G.; Rizzi, D.; Gavioli, E.; Zucchini, S.; Regoli, D.; Morari, M.; Salvadori, S.; Rowbotham, D. J.; Lambert, D. G.; Kapusta, D. R.; Calo, G. [(pF)Phe4, Arg14, Lys15]N/OFQ-NH2 (UFP-102), a highly potent and selective agonist of the nociceptin/orphanin FQ receptor. J. Pharmacol. Exp. Ther., 2005, 312, 1114-1123.
40. Rizzi, A.; Spagnolo, B.; Wainford, R. D.; Fischetti, C.; Guerrini, R.; Marzola, G.; Baldisserotto, A.; Salvadori, S.; Regoli, D.; Kapusta, D. R.; Calo, G. and studies on UFP-112, a novel potent and long lasting agonist selective for the nociceptin/orphanin FQ receptor. Peptides, 2007, 28, 1240-1251.
41. Koizumi, M.; Midorikawa, N.; Takeshima, H.; Murphy, N. P. Exogenous, but not endogenous nociceptin modulates mesolimbic dopamine release in mice. J. Neurochem., 2004, 89, 257-263.
42. Lutfy, K.; Do, T.; Maidment, N. T. Orphanin FQ/nociceptin attenuates motor stimulation and changes in nucleus accumbens extracellular dopamine induced by cocaine in rats. Psychopharmacology (Berl), 2001, 154, 1-7.
43. Maidment, N. T.; Chen, Y.; Tan, A. M.; Murphy, N. P.; Leslie, F. M. Rat ventral midbrain dopamine neurons express the orphanin FQ/nociceptin receptor ORL-1. Neuroreport, 2002, 13, 1137-1140.
44. Roberto, M.; Siggins, G. R. Nociceptin/orphanin FQ presynaptically decreases GABAergic transmission and blocks the ethanolinduced increase of GABA release in central amygdala. Proc. Natl. Acad. Sci. USA, 2006, 103, 9715-9720.
45. Roberto, M.; Madamba, S. G.; Moore, S. D.; Tallent, M. K.; Siggins, G. R. Ethanol increases GABAergic transmission at both preand postsynaptic sites in rat central amygdala neurons. Proc. Natl. Acad. Sci. USA, 2003, 100, 2053-2058.
46. Roberto, M.; Madamba, S. G.; Stouffer, D. G.; Parsons, L. H.; Siggins, G. R. Increased GABA release in the central amygdala of ethanol-dependent rats. J. Neurosci., 2004, 24, 10159-10166.
47. Sakoori, K.; Murphy, N. P. Endogenous nociceptin (orphanin FQ) suppresses basal hedonic state and acute reward responses to methamphetamine and ethanol, but facilitates chronic responses. Neuropsychopharmacology, 2008, 33, 877-891.
48. Marquez, P.; Nguyen, A. T.; Hamid, A.; Lutfy, K. The endogenous OFQ/N/ORL-1 receptor system regulates the rewarding effects of acute cocaine. Neuropharmacology, 2008, 54, 564-568.
49. Walker, J. R.; Spina, M.; Terenius, L.; Koob, G. F. Nociceptin fails to affect heroin self-administration in the rat. Neuroreport, 1998, 9, 2243-2247.
50. Wichmann, J.; Adam, G.; Rover, S.; Cesura, A. M.; Dautzenberg, F. M.; Jenck, F. 8-acenaphthen-1-yl-1-phenyl-1,3,8-triazaspiro[4.5]decan-4-one derivatives as orphanin FQ receptor agonists. Bioorg. Med. Chem. Lett., 1999, 9, 2343-2348.
51. Rover, S.; Adam, G.; Cesura, A. M.; Galley, G.; Jenck, F.; Monsma, F. J., Jr.; Wichmann, J.; Dautzenberg, F. M. High-affinity, non-peptide agonists for the ORL1 (orphanin FQ/nociceptin) receptor. J. Med. Chem., 2000b, 43, 1329-1338.
52. Kotlinska, J.; Wichmann, J.; Rafalski, P.; Talarek, S.; Dylag, T.; Silberring, J. Non-peptidergic OP4 receptor agonist inhibits morphine antinociception but does not influence morphine dependence. Neuroreport, 2003, 14, 601-604.
53. Shoblock, J. R.; Wichmann, J.; Maidment, N. T. The effect of a systemically active ORL-1 agonist, Ro 64-6198, on the acquisition, expression, extinction, and reinstatement of morphine conditioned place preference. Neuropharmacology, 2005, 49, 439-446.
54. Kuzmin, A.; Kreek, M. J.; Bakalkin, G.; Liljequist, S. The nociceptin/ orphanin FQ receptor agonist Ro 64-6198 reduces alcohol self-administration and prevents relapse-like alcohol drinking. Neuropsychopharmacology, 2007, 32, 902-910.
55. Economidou, D.; Fedeli, A.; Fardon, R. M.; Weiss, F.; Massi, M.; Ciccocioppo, R. Effect of novel nociceptin/orphanin FQ-NOP receptor ligands on ethanol drinking in alcohol-preferring msP rats. Peptides, 2006, 27, 3299-3306.
56. Higgins, G. A.; Grottick, A. J.; Ballard, T. M.; Richards, J. G.; Messer, J.; Takeshima, H.; Pauly-Evers, M.; Jenck, F.; Adam, G.; Wichmann, J. Influence of the selective ORL1 receptor agonist, Ro64-6198, on rodent neurological function. Neuropharmacology, 2001, 41, 97-107.
57. Zaveri, N. Peptide and nonpeptide ligands for the nociceptin/ orphanin FQ receptor ORL1: research tools and potential therapeutic agents. Life Sci., 2003, 73, 663-678.
58. Ishiyama, K.; Tereda, T.; Oyama, T.; Ohgi, T. Peptide derivatives and medicinal compositions. Eur. Patent EP 1, 275,657 A1, 2003.
59. Cowan, A.; Lewis, J. W.; Macfarlane, I. R. Agonist and antagonist properties of buprenorphine, a new antinociceptive agent. Br. J. Pharmacol., 1977, 60, 537-545.
60. Sadee, W.; Rosenbaum, J. S.; Herz, A. Buprenorphine: differential interaction with opiate receptor subtypes. J. Pharmacol. Exp. Ther., 1982, 223, 157-162.
61. Zaveri, N.; Polgar, W. E.; Olsen, C. M.; Kelson, A. B.; Grundt, P.; Lewis, J. W.; Toll, L. Characterization of opiates, neuroleptics, and synthetic analogs at ORL1 and opioid receptors. Eur. J. Pharmacol., 2001, 428, 29-36.
62. Bloms-Funke, P.; Gillen, C.; Schuettler, A. J.; Wnendt, S. Agonistic effects of the opioid buprenorphine on the nociceptin/OFQ receptor. Peptides, 2000, 21, 1141-1146.
63. Wnendt, S.; Kruger, T.; Janocha, E.; Hildebrandt, D.; Englberger, W. Agonistic effect of buprenorphine in a nociceptin/OFQ receptor-triggered reporter gene assay. Mol. Pharmacol., 1999, 56, 334-338.
64. Lutfy, K.; Eitan, S.; Bryant, C. D.; Yang, Y. C.; Saliminejad, N.; Walwyn, W.; Kieffer, B. L.; Takeshima, H.; Carroll, F. I.; Maidment, N. T.; Evans, C. J. Buprenorphine-induced antinociception is mediated by mu-opioid receptors and compromised by concomitant activation of opioid receptor-like receptors. J. Neurosci., 2003, 23, 10331-10337.
65. Huang, P.; Kehner, G. B.; Cowan, A.; Liu-Chen, L. Y. Comparison of pharmacological activities of buprenorphine and norbuprenorphine: norbuprenorphine is a potent opioid agonist. J. Pharmacol. Exp. Ther., 2001, 297, 688-695.
66. France, C. P.; Woods, J. H. Discriminative stimulus effects of opioid agonists in morphine-dependent pigeons. J. Pharmacol. Exp. Ther., 1990, 254, 626-632.
67. Young, A. M.; Stephens, K. R.; Hein, D. W.; Woods, J. H. Reinforcing and discriminative stimulus properties of mixed agonistantagonist opioids. J. Pharmacol. Exp. Ther., 1984, 229, 118-126.
68. Lukas, S. E.; Griffiths, R. R.; Brady, J. V. Buprenorphine selfadministration by the baboon: comparison with other opioids. NIDA Res. Monogr., 1983, 43, 178-183.
69. Boothby, L. A.; Doering, P. L. Buprenorphine for the treatment of opioid dependence. Am. J. Health Syst. Pharm., 2007, 64, 266-272.
70. Carroll, M. E.; Carmona, G. N.; May, S. A.; Buzalsky, S.; Larson, C. Buprenorphine's effects on self-administration of smoked cocaine base and orally delivered phencyclidine, ethanol and saccharin in rhesus monkeys. J. Pharmacol. Exp. Ther., 1992, 261, 26-37.
71. Mello, N. K.; Mendelson, J. H.; Bree, M. P.; Lukas, S. E. Buprenorphine suppresses cocaine self-administration in rhesus monkeys. NIDA Res. Monogr., 1989, 95, 333-334.
72. Kosten, T. R.; Rosen, M. I.; Schottenfeld, R.; Ziedonis, D. Buprenorphine for cocaine and opiate dependence. Psychopharmacol. Bull., 1992, 28, 15-19.
73. Montoya, I. D.; Gorelick, D. A.; Preston, K. L.; Schroeder, J. R.; Umbricht, A.; Cheskin, L. J.; Lange, W. R.; Contoreggi, C.; Johnson, R. E.; Fudala, P. J. Randomized trial of buprenorphine for treatment of concurrent opiate and cocaine dependence. Clin. Pharmacol. Ther., 2004, 75, 34-48.
74. Schottenfeld, R. S.; Pakes, J.; Ziedonis, D.; Kosten, T. R. Buprenorphine: dose-related effects on cocaine and opioid use in cocaine-abusing opioid-dependent humans. Biol. Psychiatry, 1993, 34, 66-74.
75. Nava, F.; Manzato, E.; Leonardi, C.; Lucchini, A. Opioid maintenance therapy suppresses alcohol intake in heroin addicts with alcohol dependence: preliminary results of an open randomized study. Prog. Neuropsychopharmacol. Biol. Psychiatry, 2008, 32, 1867-1872.
76. Ciccocioppo, R.; Economidou, D.; Rimondini, R.; Sommer, W.; Massi, M.; Heilig, M. Buprenorphine reduces alcohol drinking through activation of the nociceptin/orphanin FQ-NOP receptor system. Biol. Psychiatry, 2007, 61, 4-12.
77. Marquez, P.; Borse, J.; Nguyen, A. T.; Hamid, A.; Lutfy, K. The role of the opioid receptor-like (ORL1) receptor in motor stimulatory and rewarding actions of buprenorphine and morphine. Neuroscience, 2008, 155, 597-602.
78. Mamiya, T.; Noda, Y.; Ren, X.; Nagai, T.; Takeshima, H.; Ukai, M.; Nabeshima, T. Morphine tolerance and dependence in the nociceptin receptor knockout mice. J. Neural. Transm., 2001, 108, 1349-1361.
79. Kest, B.; Hopkins, E.; Palmese, C. A.; Chen, Z. P.; Mogil, J. S.; Pintar, J. E. Morphine tolerance and dependence in nociceptin/ orphanin FQ transgenic knock-out mice. Neuroscience, 2001, 104, 217-222.
80. Lutfy, K.; Hossain, S. M.; Khaliq, I.; Maidment, N. T. Orphanin FQ/nociceptin attenuates the development of morphine tolerance in rats. Br. J. Pharmacol., 2001, 134, 529-534.
81. Chung, S.; Pohl, S.; Zeng, J.; Civelli, O.; Reinscheid, R. K. Endogenous orphanin FQ/nociceptin is involved in the development of morphine tolerance. J. Pharmacol. Exp. Ther., 2006, 318, 262-267.
82. Khroyan, T. V.; Zaveri, N. T.; Polgar, W. E.; Orduna, J.; Olsen, C.; Jiang, F.; Toll, L. SR 16435 [1-(1-(bicyclo[3.3.1]nonan-9-yl)piperidin-4-yl)indolin-2-one], a novel mixed nociceptin/ orphanin FQ/mu-opioid receptor partial agonist: analgesic and rewarding properties in mice. J. Pharmacol. Exp. Ther., 2007, 320, 934-943.